XII NIBIT Meeting  
Siena, October 9-11 2014  
Hotel Garden  
Viale Custoza 2, Siena

Thursday October 9

12:00  Arrival/Registration/Light Lunch

14:00  Welcome addresses

Session 1. Mutated tumor antigens and adoptive cell therapy in the clinics  
Chair: Per Thor Straten (Copenhagen) and Giorgio Parmiani (Milan/Siena)

14.15  Paul Robbins (Bethesda): Targeting mutated antigens by adoptive cell therapy.

14:40  Anna Mondino (Milan): Novel strategies to improve adoptive T cell therapy for solid tumors

15:05  Per Thor Straten (Copenhagen): Cancer therapy using tumor infiltrating lymphocytes (TIL) for adoptive transfer: prospects and pitfalls

15:30  Selected Abstract:
15:45  Selected Abstract:

16:00 Coffee break

Session 2. Targeting cancer stem cells for immunotherapy  
Chair: Ruggero De Maria (Rome), Matteo Bellone (Milan)

16:30  Michele Cioffi (Madrid): Biology of cancer stem cells: an up-date

16:55  Giorgio Stassi (Palermo): Cancer stem cells: from bench to bedside

17:20  Serena Pellegatta (Milan): Immunotherapy with dendritic cells loaded with glioblastoma stem-cells: from preclinical to clinical studies

17:45  Selected Abstract:
18:00  Selected Abstract

18:15 General Assembly of the NIBIT

20:00 Dinner
Friday October 10

Session 3. Tumor microenvironment and metabolism
Chair: Paolo Dellabona (Milan) and Ruggero Ridolfi (Meldola)

8:30 Federica Marchesi (Milan): Tertiary Lymphoid Tissue: a key player of the tumor microenvironment

8:55 Claudio Tripodo (Palermo): Common stromal motifs influence the pathobiology of myeloid and lymphoid malignancies

9:20 Vincenzo Russo (Milan): LXR dependent and independent effects of oxysterols on immunity and tumor growth

9:45 Maria Pia Protti (Milan): Th22 cells in multiple myeloma: frequency and tumor promoting function

10:10 Selected Abstract
10:25 Selected Abstract

10.40 Coffee break

Session 4. New developments in immuno-oncology
Chair: Paola Zanovello (Padua) and Massimo Di Nicola (Milan)

11:00 Davide Bedognetti (Doha): Illuminating the molecular mechanisms of response to cancer immunotherapy

11:25 Soldano Ferrone (Boston): HLA class I antigen and PD-L1 expression and clinical course of the disease in intra hepatic cholangiocarcinoma

11:50 Hervé Fridman (Paris): Driving immunotherapy by tumor phenotype

12:15 Barbara Seliger (Halle): Role of microRNAs for immune escape of tumors

12:40 Selected Abstract
12:55 Selected Abstract

13:10 Lunch
Session 5. Vaccines: Pitfalls and promises  
Chair: Enrico Proietti (Rome) and Pier Francesco Ferrucci (Milan)

14:30 Giorgio Parmiani (Milan): Cancer vaccines: still promising?
14:55 Carl Figdor (Nijmegen): Dendritic cells in cancer-immunotherapy: next steps to take
15:20 Pedro Romero (Lausanne): Peptide vaccinations of cancer patients

Invited Abstract
15:45 Elisabeth Griffith (Buffalo): Decitabine induced NY-ESO1 expression as a therapeutic target in myelodysplasia: preliminary results from a phase I study

16:00 Selected Abstract

16:15 Coffee break

Session 6. Checkpoint blockade and targeted therapies in melanoma and other tumors  
Chairs: Michele Maio (Siena) and Paola Queirolo (Genoa)

16:30 Jeffrey Weber (Tampa): Overview of check-point blockade agents
16:55 TBD: Checkpoint blockade in thoracic malignancies
17:20 Ramy Ibrahim (Gaithersburg): MedImmune Phase I studies
17:45 Michele del Vecchio (Milano) BRAF and MEK inhibitors

Invited Abstract
18:10 Pierre Ferrè (Gèneve): W014A, a PD-1 decoy peptide blocking both PD-1 immune checkpoint ligands, PD-L1 and PD-L2

Selected Abstract
18:25

20:00 Social Dinner
Saturday October 11

Session 7: Prognostic and predictive biomarkers in bio-immunotherapy  
Chairs: Licia Rivoltini (Milan) and Graham Pawelec (Tübingen)

8:30 Matteo Ramazzotti (Firenze): A Systems Level approach for the discovery of prognostic signatures through big data analyses

08:55 Andrea Anichini (Milan): Mechanisms of susceptibility and/or resistance to ipilimumab?

9:20 Benjamin Weide (Tübingen): Biomarkers and survival in the course of Ipilimumab

9:45 Cristina Maccalli (Siena): Immunologic biomarkers and response to therapy

10:10 Coffee break

Session 8. Ongoing and prospective NIBIT activities and collaborations  
Chair: Alberto Amadori (Padua) and Alessandro Testori (Milan)

10:30 Anna Maria Di Giacomo (Siena): NIBIT clinical studies

10:45 Diana Giannarelli (Rome): Design of immunotherapeutic studies

11:00 Luigi Buonaguro (Naples): Cancer vaccines in hepatocarcinoma

11:15 Massimo Guidoboni (Meldola): The NIBIT effect: how the Network can promote synergies in developing cellular therapies

11:30 TBD

11:45 TBD

12:00 Round Table: Clinical research on cancer Bio-Immunotherapy in Italy: a near miss or an opportunity to catch?"

13:30 Lunch

Adjourn